Provided by Tiger Trade Technology Pte. Ltd.

Compugen

2.04
-0.0200-0.97%
Post-market: 2.060.0200+0.98%18:38 EDT
Volume:141.85K
Turnover:290.45K
Market Cap:192.89M
PE:5.39
High:2.09
Open:2.04
Low:2.01
Close:2.06
52wk High:2.38
52wk Low:1.13
Shares:94.55M
Float Shares:91.62M
Volume Ratio:0.87
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3783
EPS(LYR):0.3783
ROE:44.84%
ROA:14.42%
PB:1.88
PE(LYR):5.39

Loading ...

Compugen Ltd. Director Sanford S. Zweifach Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18

Compugen Ltd. CFO David Silberman files initial beneficial ownership statement

Reuters
·
Mar 18

Compugen files Form 3 initial beneficial ownership statement for director Eran Perry

Reuters
·
Mar 18

Compugen Ltd. files Form 3 initial beneficial ownership statement for President and CEO Ophir Eran

Reuters
·
Mar 18

Compugen names Chief Medical Officer Michelle Mahler in initial beneficial ownership filing

Reuters
·
Mar 18

Compugen files Form 3 initial beneficial ownership statement for SVP Business Development Zurit Levine

Reuters
·
Mar 18

Compugen Ltd. Director Mathias Hukkelhoven Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18

Compugen files Form 3 as director Michele Holcomb reports 15,000 ordinary shares

Reuters
·
Mar 18

Compugen Ltd. director Gilead Halevy files initial beneficial ownership statement

Reuters
·
Mar 18

Compugen Ltd. COO Pierre Ferre files initial beneficial ownership statement

Reuters
·
Mar 18

Compugen Ltd. Director Anat Cohen-Dayag Files Initial Beneficial Ownership Statement

Reuters
·
Mar 18

Compugen Ltd. files initial beneficial ownership statement for SVP Research & Discovery Sharon Kredo Russo

Reuters
·
Mar 18

Truist Financial Sticks to Its Buy Rating for Compugen (CGEN)

TIPRANKS
·
Mar 03

Compugen Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 02

Compugen Extends Cash Runway to 2029 and Swings to Profit on AstraZeneca Deal and Clinical Progress

TIPRANKS
·
Mar 02

CORRECTED-Israel's Compugen Q4 revenue beats on rilvegostomig royalties

Reuters
·
Mar 02

Compugen Ltd. Publishes Corporate Presentation on AI-Driven Immuno-Oncology Antibody Pipeline

Reuters
·
Mar 02

Compugen posts FY 2025 revenue of USD 72.8 million (+161.0%)

Reuters
·
Mar 02

Compugen Q4 EPS $0.60 Beats $0.05 Estimate, Sales $67.332M Beat $1.357M Estimate

Benzinga
·
Mar 02

Press Release: Compugen Reports Fourth Quarter and Full Year 2025 Results

Dow Jones
·
Mar 02